The 4DMedical Ltd (ASX: 4DX) share price is in focus after the company posted a 21% lift in revenue to $7.1 million for FY26, with adjusted net loss improving 7% to $32.9 million.
What did 4DMedical report?
- Revenue from ordinary activities up 21% to $7.1 million
- Adjusted net loss down 7% to $32.9 million
- Statutory net loss expanded to $203 million (from $30.1 million a year ago), driven by significant non-cash items
- Gross margins remained above 90%
- No dividend declared or paid
- Net tangible assets per share improved to $0.17 (from negative $0.02)
What else do investors need to know?
4DMedical’s underlying SaaS revenue climbed 23%, supported by strong growth from B2B hospital and radiology partners, third-party AI distributors, and global medical technology companies. The loss at the statutory level included a major non-cash impactâremeasurement of the Pro Medicus loan and associated derivative financial instrumentâreflecting complex accounting treatment rather than core business cash outflows.
The company raised $233 million through share placements and finished the year with a robust $278 million in cash, positioning it well for ongoing investment and expansion. No dividends were declared for FY26.
What did 4DMedical management say?
Dr. Andreas Fouras, Managing Director and CEO, commented:
4DMedical has maintained strong momentum throughout FY26, improving our adjusted net loss result and strengthening our balance sheet so we can accelerate future growth initiatives.
What’s next for 4DMedical?
Looking ahead, 4DMedical recently completed the acquisition of contextflow GmbH, an Austrian lung cancer screening technology company. The group also led a strategic investment in RevealDx, securing exclusive distribution rights for RevealAI-lung across key markets, including Europe, Australia, and New Zealand.
Management plans to continue scaling its commercial partnerships and integrating new technologies, while building a globally competitive medical imaging and AI platform.
4DMedical share price snapshot
Over the past 12 months, 4DMedical shares have risen nearly 700%, far outpacing the All Ordinaries Index (ASX: XAO).
The post 4DMedical share price rises as FY26 revenue climbs, losses moderate appeared first on The Motley Fool Australia.
Should you invest $1,000 in 4DMedical right now?
Before you buy 4DMedical shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 4DMedical wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Here are the top 10 ASX 200 shares today
- These are the 10 most shorted ASX shares
- These are the 10 most shorted ASX shares
- 4DMedical shares are up 670% â but why have they halved?
- Are Pro Medicus shares now too cheap to ignore?
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.